CJC-1295 with DAC is a tetrasubstituted GHRH analogue engineered with Drug Affinity Complex (DAC) technology, which enables covalent binding to serum albumin via a reactive maleimide group. This modification significantly extends its plasma half-life to approximately 6–8 days in research models, compared to minutes for endogenous GHRH.
This prolonged bioavailability profile allows researchers to study sustained GH axis stimulation without repeated administration, making it particularly useful for long-duration endocrine research protocols and pharmacokinetic modelling studies. Studies have characterised its dose-response relationship with GH and IGF-1, and its effects on nitrogen balance and body composition in preclinical settings.
Research has also investigated the implications of continuous versus pulsatile GH axis stimulation on downstream biological endpoints, using CJC-1295 with DAC as a model compound for sustained GHRH receptor occupancy. Its albumin-binding mechanism is also of interest in the broader context of DAC technology applications in peptide pharmacology research.
Format: Lyophilised powder | Purity: ≥99% by HPLC | For Research Use Only
